ProNAi Therapeutics IPO

7/17/2015

IPO

$137,700,000

We currently anticipate that we will use the net proceeds from this offering as follows: approximately $43.0 million to fund our ongoing Wolverine Phase 2 trial, our planned Brighton Phase 2 trial that we expect to initiate in mid-2015 and manufacturing activities related to these trials; approximately $40.0 million to fund other planned future Phase 2 trials related to PNT2258 and manufacturing activities related to these trials; approximately $5.0 million to support non-clinical activities and preclinical activities related to PNT2258, including activities related to its mechanism of action; and approximately $7.0 million to further develop our DNAi technology platform and broaden our pipeline of DNAi-based product candidates. The remainder of the net proceeds will be used for working capital and other general corporate purposes as well as to pay the approximately $5.5 million of cumulative accrued dividends to our Series B and Series B-1 redeemable convertible preferred stockholders

Publicly-held

Biopharmaceutical

885 West Georgia St. 2150
Vancouver BC, V6C 3E8
Canada

ProNAi Therapeutics, Inc. (NASDAQ: DNAI) is a biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi, to advance a next generation of therapies for patients with cancer and other complex genetic diseases.